Table 2.
Treatment Patterns by Sex for Patients With Lung Cancer From UH (2005–2020) and SEER (2005–2018) Databases
| Feature | UH |
SEER |
||||
|---|---|---|---|---|---|---|
| Male |
Female |
p Value | Male |
Female |
p Value | |
| 4366 (49%) | 4543 (51%) | 378,452 (52.2%) | 346,566 (47.8%) | |||
| Chemo, n (%)a | ||||||
| Yes | 1941 (44.5) | 1985 (43.7) | 0.48 | 153,915 (40.7) | 132,425 (38.2) | <0.001 |
| Surgery, n (%)a | ||||||
| Yes | 1005 (23) | 1200 (26.4) | <0.001 | 72,937 (19.3) | 80,765 (23.3) | <0.001 |
| Immunotherapy or PD-L1 inhibitors, n (%)a | ||||||
| Yes | 1074 (24.6) | 1028 (22.6) | 0.03 | — | — | — |
| Targeted therapy, n (%)a | ||||||
| Yes | 136 (3.1) | 167 (3.7) | 0.16 | — | — | — |
| Time to chemo, n (%)a | ||||||
| ≤30 d | 723 (48.2) | 691 (45.2) | 0.10 | — | — | — |
| >30 d | 778 (51.8) | 839 (54.8) | — | — | ||
| Time to immunotherapy, n (%)a | ||||||
| ≤50 d | 517 (50.6) | 468 (48.2) | 0.30 | — | — | — |
| >50 d | 505 (49.4) | 503 (51.8) | — | — | ||
| Time to surgery, n (%)a | ||||||
| ≤30 d | 286 (51.6) | 331 (52.8) | 0.73 | — | — | — |
| >30 d | 268 (48.4) | 296 (47.2) | — | — | ||
| Time of chemo, n (%)a | ||||||
| ≤60 d | 421 (41.6) | 345 (35.6) | 0.007 | — | — | — |
| >60 d | 592 (58.4) | 623 (64.4) | — | — | ||
| Compliance to treatmentb | ||||||
| Appointments cancelled (mean, %) | 22.2 | 21.4 | 0.86 | |||
Chemo, chemotherapy; PD-L1, programmed death-ligand 1; SEER, Surveillance, Epidemiology, and End Results; UH, University Hospital.
a
Compared with Pearson’s chi-square test.
b
Compared with Kruskal-Wallis test.